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(MNGIE) is a rare autosomal metabolic disorder caused by
thymidine phosphorylase (TP) deficiency. Successful therapeu-
tic interventions for this disease rely on a means for efficient
and long-lasting circulation of the TP enzyme. In this study
we exploit lentiviral transduction of hematopoietic stem cells
and an erythroid cell line (BEL-A) to generate reticulocytes
that contain active TP. Significant loss of overexpressed TP
during erythroid differentiation can be reduced by addition
of the ubiquitination inhibitor MG132. However, the ubiquiti-
nation sites are located in the substrate binding site in human
TP, and their removal abolished enzyme activity. Examination
of the TP structure and mechanism suggested that these sites
are only exposed in the absence of substrate. We show that sup-
plementation of culture media with thymidine during differen-
tiation reduces enzyme degradation, doubling the amount of
TP retained in reticulocytes. This study provides proof of prin-
ciple that therapeutic reticulocytes expressing TP can be gener-
ated in vitro and that ubiquitin-mediated degradation can be
subverted through masking ubiquitination sites to ensure
retention of human TP in reticulocytes following erythroid dif-
ferentiation.Received 10 March 2020; accepted 25 March 2020;
https://doi.org/10.1016/j.omtm.2020.03.029.
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Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
is an autosomal recessive metabolic disorder1 that usually manifests
during early teens, with an average life expectancy of 37.5 years.2,3
The disease is very rare, with an estimated occurrence in the
population of 1:1,000,000 but this may be an underestimate4 due
to the varied clinical presentation, which includes severe gastrointes-
tinal dysmotility, cachexia, peripheral neuropathy, diffuse leukoence-
phalopathy, and mitochondrial abnormalities.3
MNGIE is caused by mutations in the TYMP gene, which encodes the
thymidine phosphorylase (TP) enzyme. TP catalyzes the phosphorol-
ysis of thymidine (dThd) and deoxyuridine (dUrd) to thymine or uri-
dine, and 2-deoxy ribose 1-phosphate (2DR1P) in the cytosol. Here it822 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2
This is an open access article under the CC BY-NC-ND license (httpplays a key role in pyrimidine salvage, recovering nucleosides after
DNA/RNA degradation.5 Homozygous or compound heterozygous
mutations in the TYMP gene cause a drastic reduction in protein
expression or activity, which results in thymidine accumulation,
and subsequently leads to an imbalanced intramitochondrial deoxy-
nucleotide pool.4,6–8 This is thought to destabilize mitochondrial
DNA by affecting mitochondrial DNA repair and replication, result-
ing in the broad variety of symptoms.9
Although significant progress in the understanding on the molecular
basis of the MNGIE has been made, we still lack an effective treat-
ment. Currently, treatment is largely based on patient symptomman-
agement, which include nutritional supplements, prevention of infec-
tions, and pain relief. Research has focused on developing treatments
to remove metabolites using hemodialysis, hematopoietic stem cell
transplantation (HSCT), and TP enzyme replacement therapy.4
Although hemodialysis is beneficial, the effect is transient, and dial-
ysis is required every 3 h.8 HSCT can restore expression of TP and
improve the biochemical parameters, but transplantation has
inherent risks, and achieving a suitable donor match can be chal-
lenging.10 A different method of increasing TP activity is the use of
enzyme replacement therapy in platelets and red blood cells. Platelets
naturally express high levels of TP, and platelet transfusion corrected
the nucleoside imbalance in blood plasma. However, the improve-
ment was temporary and multiple platelet transfusions per week
are necessary for long-term improvements.4
The most promising approach for enzyme replacement is the use of
erythrocyte encapsulated TP (EETP). Erythrocytes do not normally
express TP, but hypotonic hemolysis and isotonic resealing11 can be
used to encapsulate Escherichia coli TP in autologous red blood020 ª 2020 The Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Endogenous TP Expression and Activity
(A, D, and G) Representative flow cytometry histograms show the expression levels of TP in 1  105 fixed and permeabilized cells in (A) isolated CD34+ cells, isolated native
reticulocytes, red blood cells (RBCs), and isolated platelets, (D) in vitro-cultured erythroblasts and reticulocytes, and (G) in expanded BEL-A and differentiated BEL-A cells. (B,
E, and H) The average measurements are shown for 1  105 fixed and permeabilized cells by flow cytometry in mean fluorescence intensity (arbitrary units) for (B) isolated
blood cells, (E) in vitro-cultured erythroblasts and reticulocytes, and (H) expanding BEL-A (proerythroblasts), differentiating BEL-A on day 6 (polychromatic), and BEL-A-
derived reticulocytes. Data are represented as mean ± SEM (N = 6). (C and F) TP activity was measured using 1 106 lysed cells by a spectrophotometry-based assay (see
Materials and Methods, and Figure S1 for example titration curve). 1 U (mmol/min) is defined as the amount of the enzyme that catalyzes the conversion of mmol of thymidine
per minute. (C) TP activity in isolated CD34+ cells, reticulocytes, and red blood cells, and, as a positive control, TP activity was measured in 1 107 platelets (N = 3 ± SEM). (F)
TP activity was measured in 1  106 in vitro-cultured red blood cells.
www.moleculartherapy.orgcells.12 This has been successfully used in the clinic, achieving pro-
longed cessation of the MNGIE clinical phenotype by reducing
plasma nucleoside levels.13,14 Although this method is promising,
the methodology of encapsulation within erythrocytes using hypo-
tonic lysis can compromise the lifespan of the erythrocytes, and pa-
tients can develop antibodies against the bacterial enzyme.15 Recently,
progress has been made in the ex vivo culture of reticulocytes from
CD34+ stem cells in vitro, with more than 10 mL of leukofiltered
packed reticulocytes produced using good manufacturing practice
(GMP).16 This, and the recent development of an adult phenotype
erythroid cell line (BEL-A),17 led us to investigate the possibility of us-
ing genetically modified reticulocytes as vehicles for TP transport as a
novel therapy for MNGIE.
RESULTS
Endogenous TP Expression in Erythroid Progenitors,
Reticulocytes, and Erythrocytes
Before exploring the possibility of genetically modifying reticulocytes
to express TP, we first confirmed the baseline endogenous expression
and TP activity levels in isolated hematopoietic CD34+ stem cells,
standard donor-derived reticulocytes, and erythrocytes. ExpressionMoleculwas assessed by flow cytometry on fixed and permeabilized cells,
and TP activity was determined on cell lysates using a spectropho-
tometer-based assay whereby the difference in absorbance levels of
thymine, in the presence of TP, after 60 min at 37C was measured
(Figure S1).18 As expected, both assays confirmed a low endogenous
expression and activity of TP in CD34+ hematopoietic stem cells and
native peripheral blood reticulocytes and no TP expression or
activity in red blood cells (Figures 1A–1C). Freshly isolated platelets
from peripheral blood were included as a positive control (Figures
1B and 1C).
Endogenous TP expression and activity in erythroid cells differenti-
ated in vitro from CD34+ hematopoietic stem cells was examined.
The different stages of erythroid maturation in our in vitro culturing
system has been reported previously.19 Hereafter, we refer to the days
in culture and their approximate stage of differentiation in parenthe-
ses based on this knowledge. Figures 1D–1F show that the expression
of endogenous TP and activity in cultured day 8 (proerythroblast)
and day 12 (polychromatic erythroblast) is low. The expression and
activity of filtered in vitro-cultured reticulocytes is also comparable




Figure 2. Lentiviral Overexpression of Human TP in
Cultured Reticulocytes
(A and C) CD34+ hematopoietic stem cells and expanding
BEL-A cells were transduced using lentivirus with TP
cDNA generating cTP (A) and bTP (C) cells and subse-
quently differentiated into reticulocytes. TP expression
was assessed at different time points during differentia-
tion by flow cytometry, where at each indicated time point
1  105 cells were fixed and permeabilized and subse-
quently labeled with a TP antibody. Expression is
normalized to endogenous expression of TP at the pro-
erythroblast stage (N = 6 ± SEM). (B) Expression by
western blotting of TP, Band3, and GAPDH during dif-
ferentiation. Equal cell numbers were loaded (1  106
cells per lane). (D) TP activity was measured in 1  106
cTP cells using the spectrophotometry-based assay at
the indicated time point during differentiation (N = 6). (E)
Time course of TP activity in whole cells using the spec-
trophotometry-based assay. Decrease in thymidine
concentration was measured in the supernatant of 1 
106 cells at the indicated time points (N = 3).
Molecular Therapy: Methods & Clinical Developmentexpression in an expanding erythroid cell line, BEL-A, which has the
capacity to differentiate into reticulocytes, which are comparable to
in vitro-cultured reticulocytes.17 The advantage of also using BEL-A
cells is that these provide a sustainable source of cells that can be
genetically modified and stored frozen with the modification main-
tained indefinitely, whereas CD34+-derived cultures are finite and
need to be reinitiated each time. Expanding BEL-A cells (which are
comparable to proerythroblast erythroblasts) have a low endogenous
TP expression (Figures 1G and 1H), and the BEL-A-derived reticulo-
cytes exhibit a very low TP expression (Figure 1H), comparable to
CD34+-derived cultured reticulocytes (Figure 1E) and in vivo-isolated
reticulocytes (Figure 1B).
ExogenousOverexpression of TP in In VitroCD34+Reticulocytes
and BEL-A-Derived Reticulocytes Using Lentivirus
Cultured erythroid progenitors expressing TP (cTP) and expanding
BEL-A cells expressing TP (bTP) were created by stably transducing
the cells with lentivirus-expressing TP cDNA. Subclones were created
from the polyclonal bTP population by blind single cell sorting using
fluorescence-activated cell sorting (FACS). Day 7 cTP (proerythro-
blast) cells and expanding bTP (proerythroblast) cells exhibited a
25- and 45-fold increase, respectively, in TP enzyme expression by
flow cytometry compared to endogenous expression of TP in un-
transduced (UT) proerythroblast cells (Figures 2A and 2B).
The cTP cells were differentiated and TP expression was measured at
the indicated days by flow cytometry (Figure 2A) and by western blot824 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020(Figure 2B). bTP expression was measured dur-
ing differentiation at day 4 (basophilic erythro-
cytes), day 6 (polychromatic erythrocytes), and
day 10 (orthochromatic erythrocytes) and in re-
ticulocytes (see Figure 2C). Although TPexpression in cTP and bTP reticulocytes is observed to be 6- and
12-fold increased relative to UT proerythroblast levels, a striking
decline of expression is observed during terminal differentiation.
The activity assay confirmed the presence of active enzyme in cTP
proerythroblasts with an approximate concentration of 1.2  108
U/cell (Figure 2D). Subsequently, samples were taken during differen-
tiation at the indicated time points, and activity was measured. We
observed an approximately 3-fold reduction of activity in cTP-filtered
reticulocytes compared to cTP proerythroblasts, which have a final
concentration of 4.4  109 U/cell. A 3-fold reduced expression
was also observed using flow cytometry between cTP proerythroblasts
and cTP reticulocytes.
To test whether thymidine and thymine are able to cross the intact
reticulocyte cell membrane, and whether TP is active in the intracel-
lular environment of reticulocytes, an activity assay was performed
on whole cells. Thymidine was added to the media of 1  106 cells
at 37C, and subsequently the concentration of thyminewasmeasured
in the supernatant after 1, 3, 6, and 24 h of incubation. Lysed cTP re-
ticulocytes were used as a control, which were incubated with thymi-
dine for 1 h (Figure 2E). As expected, the increase in thymine produc-
tion is slower in whole-cell supernatants, compared to lysed cells, but
after a 24-h incubation period, a comparable concentration of thymine
was measured in the supernatant compared to lysed cells. This indi-
cates that intact cells expressing TP can phosphorylate thymidine,
and thymidine and thymine are able to cross the cell membrane.
Figure 3. Human TP Is Lost during Differentiation via
the Ubiquitination Pathway
To determine the mechanism responsible for TP degra-
dation, 1  106 day 14 cTP cells (which correspond to the
polychromatic erythroblast stage) were incubated with
either 5 mMMG132 or 10 mM leupeptin or left untreated at
37C for 24 h. (A) Graph shows expression levels
measured using flow cytometry before addition of the in-
hibitors (start) and after incubation with the indicated in-
hibitors or an equivalent concentration of DMSO vehicle as
a control (N = 3 ± SEM). (B) Ribbon structure of the human
TP enzyme. The a domain is depicted in blue, and the b
domain is depicted in beige. The ubiquitination residues
that correspond to the known murine ubiquitination sites
within the TP active site are labeled in purple.
www.moleculartherapy.orgThe cTP cells are morphologically comparable to UT cells by cytospin
during differentiation (Figure S2A), and we confirmed by confocal
microscopy that TP is localized in the cytoplasm in reticulocytes (Fig-
ure S2B). Expression of essential membrane proteins was measured
on unmodified control and cTP reticulocytes, and no differences
were observed (Figure S2C). The deformability and size of the cTP-
derived reticulocytes was measured using an automated rheoscope
cell analyzer (ARCA).20 This showed that the deformability of cTP re-
ticulocytes is comparable to that of the unmodified control reticulo-
cytes and that they have a comparable size (Figure S2D).
TP Is Degraded by the Ubiquitin Degradation Pathway in
Erythroblasts
The substantial loss of TP enzyme expression during differentiation
suggested to us that TP is likely being actively degraded during termi-
nal differentiation. Ubiquitination and lysosomal degradation are the
main cellular degradation pathways during erythropoiesis.21 To test
whether exogenous TP degradation during differentiation is due to
ubiquitination or lysosomal degradation, we subjected the day 14
(orthochromatic erythrocytes) cTP cells to the proteasome inhibitor
MG132, or a lysosomal degradation inhibitor, leupeptin,22,23 during
culture. TP expression was first measured on day 14 and then 24 h
after incubation with MG132, leupeptin, or the vehicle control.
Figure 3A shows that application of MG132 inhibited degradation,
whereas leupeptin and the vehicle control had no effect. This
demonstrates that ubiquitination during erythroid differentiation is
a significant cause of human TP protein degradation.Molecular Therapy: MethodsModeling of Human TP and Mutagenesis of
the Ubiquitination Site
Ubiquitination is an essential part of the
erythroid cell maturation process,24 and there-
fore the global inhibition of ubiquitination-
mediated degradation using proteasome inhibi-
tors such as MG132 is not a viable solution to
enhancing TP levels in reticulocytes. Examina-
tion of the human crystal structure of the TP
dimer (protein data bank: 2J0F.pdb) showed
that the protein is composed of two homo-dimers, each consisting of a six-a helix a domain and an a/b domain
that consists of an antiparallel b sheet surrounded by a helixes.25
Interestingly, these domains can rotate 8 relative to each other
upon substrate binding.25 Without substrate present, TP is in an
open conformation, while binding to thymidine and phosphate
causes the enzyme to close.25 Kinetic studies conducted on E. coli
and rabbit TP protein have shown that there is a sequential mecha-
nism of binding whereby the substrate thymidine is the first to
bind, and 2-deoxyribose-1-phosphate (2dR1P) is the last to be
released.26
Human and mouse TP proteins are 81% identical, and sequence
comparison confirmed that two known ubiquitination sites located
at residues 115 and 221 in the mouse TP enzyme27 are conserved in
the human TP structure. Examination of the structures suggested to
us that both conserved lysines are an integral part of the thymidine
binding site, and therefore the alteration of these important residues
could abolish TP activity or stability because the active site is altered
(see Figure 3B). The two lysine residues in human TP were
exchanged for arginine residues to preserve the active site structure
but remove the ubiquitination sites, making TP-mutant (mut). This
enzyme was expressed in both day 3 in vitro cultured erythrocytes
(cTP-mut) and expanding BEL-A cells (bTP-mut), and the cells
subsequently differentiated. The TP-mut expression levels achieved
were comparable to day 6 cTP and expanding bTP cells (see Figures
4A and 4B), but no TP activity was detected in the cTP-mut retic-
ulocyte (Figure 4C). This supports our conjecture that the mutations& Clinical Development Vol. 17 June 2020 825
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Figure 4. Mutagenesis of the Ubiquitination Sites in
the TP Enzyme
(A and B) CD34+ hematopoietic stem cells or expanding
BEL-A cells were transduced with TP-mut, a version of the
enzyme that had the two mutated ubiquitination sites within
the substrate binding domain, generating cTP-mut (A) and
bTP-mut (B). The TP-mut overexpressing cells were sub-
sequently differentiated into reticulocytes. TP expression
was assessed at different time points during differentiation
by flow cytometry as indicated, where 1  105 cells were
fixed and permeabilized and subsequently stained with a TP
antibody. Expression was normalized to endogenous
expression of TP in proerythroblasts (N = 5 ± SEM). (C and
D) TP activity wasmeasured by a spectrophotometry-based
assay in 1  106 lysed cTP-mut proerythroblast and re-
ticulocytes (C) and bTP-mut cells during differentiation (D),
which shows that the expressed mutant TP enzyme has no
activity compared to cTP cells at the same stage of devel-
opment (N = 5 ± SEM).
Molecular Therapy: Methods & Clinical Developmentcompromise the enzyme activity and stability. Therefore, either the
enzyme active site would need to be reengineered to retain activity
but remove ubiquitin sites, or an alternate means of disrupting TP
ubiquitination is required.
TP Degradation Is Reduced by Thymidine Supplementation
After further examination of the molecular human TP structure we
observed that the two ubiquitination sites that correspond with mu-
rine TP would only be available for ubiquitination in the absence of
substrate.We therefore hypothesized that supplementation of the cul-
ture media with TP enzyme substrate thymidine would result in a
closed TP structure, reducing its degradation by obscuring access to
the lysine’s ubiquitination sites in the active site. However, previous
reports have shown that the addition of thymidine can arrest the
cell cycle and also inhibit cell growth in K562 cells at a concentration
of 1 mM.28,29 To determine whether increased thymidine concentra-
tions in our culture media could prevent TP degradation, media were
daily supplemented with 0.5 mM thymidine starting at different
points during differentiation. We confirmed an increase in cell death
and inhibition of differentiation when thymidine was added early
during in vitro culture, e.g., on day 0 of differentiation (data not
shown). To circumvent this, 0.5 mM thymidine supplementation
was added daily during differentiation, from day 14 (polychromatic
erythroblast stage) in cTP, which is approximately the point when
overexpressed human TP is observed to be degraded. A growth curve
confirmed that the addition of thymidine from day 14 did not affect
cell growth (Figure 5A). This maneuver doubled TP enzyme abun-
dance in cTP reticulocytes (Figure 5B) compared to cells produced us-
ing the standard differentiation media, which was not supplemented
with thymidine. The enzyme activity assay for the thymidine supple-
mented cTP was not significantly different from the untreated CTP,
and we presume that this is due to the cells already containing excess826 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2thymidine before lysis, which distorts the assay. As an additional con-
trol we also added a known TP inhibitor (TPI), and we show that this
significantly reduces the TP activity (Figure 5C).DISCUSSION
This study has demonstrated for the first time that exogenous human
TP can be overexpressed using lentivirus transduction of the TP
cDNA in CD34+ hematopoietic cells and in an erythroid line,
BEL-A. These cells were subsequently expanded and differentiated
to reticulocytes with confirmed retention of TP.We have also demon-
strated that although it is possible to express TP in in vitro-cultured
reticulocytes, the enzyme is degraded by ubiquitination during differ-
entiation, limiting the abundance of TP per reticulocyte. Ubiquitina-
tion is a necessary process during differentiation to remove non-
erythroid and non-essential proteins, and therefore this presents a
significant barrier to the expression of exogenous proteins for thera-
peutic purposes during red blood cell development. To circumvent
this problem, we propose that a first step for overexpressing proteins
is the removal of known or putative ubiquitination sites that are iden-
tified in the sequence of exogenous proteins, to prevent loss during
degradation. For enzymes where the ubiquitination site is an integral
part of the substrate binding site such as in the case of TP, an alterna-
tive strategy is needed, as an alteration of the ubiquitination motif
within the active site can disrupt activity. Our novel observation
shown here for TP is that inclusion of the TP enzyme substrate thymi-
dine increases the abundance of the TP in reticulocytes, likely by
masking the enzyme ubiquitin sites. Although thymidine is known
to be toxic to cells, we show that this can be achieved by supplement-
ing the culture medium with substrate (in this case thymidine) during
the late stages of terminal differentiation. Furthermore, since patients
have a concentration of >3 mmol/L of thymidine in their blood,020
Figure 5. TP Expression Is Significantly Increased by
Supplementing the Culturing Media with Thymidine
The expression TP in cTP and cells during differentiation
was increased by supplementing the culturing media with
0.5 mM thymidine every 24 h from day 14 (polychromatic
stage) in cTP cells. (A) Growth curve shows the fold increase
in cell number during differentiation with the absence or
addition of 0.5 mM thymidine. (B) Expression of TP was
measured by flow cytometry using 1  105 fixed and per-
meabilized reticulocytes from cultures either untreated in
standard media or treated with media supplemented by
thymidine (N = 4 ± SEM). (C) Specific TP activity was
confirmed by an activity assay where we used a thymidine
phosphorylase inhibitor (TPI) as a negative control.
www.moleculartherapy.orgthis should maintain TP in reticulocytes while they mature to red
blood cells.
A clinical trial in aMNGIE patient conducted by Bax and colleagues30
successfully encapsulated a therapeutic dose of 51 U of E. coli-pro-
duced TP in 1010 erythrocytes, whereby 1 U of TP is defined as the
activity required to convert 1.0 mmol of thymidine to thymine per
minute. Our cTP-cultured erythroblasts had an average expression
of TP corresponding to 84 U in 1010 cells. The expression level de-
creases during differentiation and results in an activity corresponding
to 44 U in 1010 reticulocytes. We show that TP expression can be
doubled in reticulocytes by daily addition of thymidine in the culture
medium during the late stages of differentiation. Although the addi-
tion of thymidine did prevent degradation, we acknowledge that TP
will still be partially lost in the cytosol surrounding the nucleus during
enucleation, and some loss may also occur during the process of retic-
ulocyte maturation when cells reduce in size.31
The advantage of the use of in vitro-cultured reticulocytes modified
genetically to express and retain TP is that these cells overproduce
the enzyme during normal differentiation and have not been sub-
jected to a damaging hypotonic lysis, which is required for the encap-
sulation of TP in red blood cells. In addition, since the cultured retic-
ulocytes are newly synthesized nascent red blood cells, they are
expected to have a normal red blood cell lifespan of up to 120 days,
potentially reducing the number of transfusions needed for patients
compared to using donated blood derived red blood cells that is a
mixture of ages.
The utility of in vivo animal models to assess survival and efficacy
of transfused human red blood cells is limited by the short time
frame (48–72 h) in which these cells are able to circulate, even
where immunocompromised (macrophage-depleted NSG mice)
mouse models have been employed,16 and although a mouse
model that recapitulates the MNGIE phenotype has been previ-
ously described,32 such a model does not exist on a NSG back-
ground. As such, there is currently no way to pre-assess the sur-Moleculvival or efficiency of excess thymidine removal from sera by
modified red blood cells in circulation. Nevertheless, data derived
from a single injection using autologous in vitro-cultured reticulo-
cytes suggest that these cultured reticulocytes have a half-life of
28 ± 2 days, which was comparable to a normal red blood cell
transfusion.33 Therefore, the use of modified in vitro-cultured re-
ticulocytes with TP could decrease the frequency of transfusions
needed, which would reduce the risk of transfusion-related symp-
toms. Another advantage of using in vitro-cultured TP reticulo-
cytes is that we have used unmodified human TP, which is unlikely
to induce an immune response.
In summary, this study has provided the first proof of principle
demonstration of the enhancement of ex vivo-produced reticulo-
cytes, from either CD34+ cells or an erythroid line, by engineering
the cells during red cell development to overexpress TP as a novel
cellular therapy treatment for MNGIE. The CD34+-derived engi-
neered reticulocytes could be made autologous or allogeneic, and
because these are red blood cells that have lost their nuclei, there
is no anticipated regulatory barrier to using lentivirus on the cells.
Given that GMP-compliant production of reticulocytes is now
feasible for small volumes in a process amenable to modification
by overexpressing enzymes, and a proof-of-principle autologous
transfusion into a volunteer has been conducted and further allo-
genic trials are planned,34,35 the enhancement of reticulocyte func-
tion through lentivirus transduction of erythroid precursors may
represent an early therapeutic use of in vitro-cultured blood in the
clinic. We acknowledge that although the culture efficiency of the
BEL-A cells and scalability need to be improved and a suitable
GMP-compatible erythroid line needs to be produced, the produc-
tion of erythroid lines containing overexpressed therapeutic proteins
represents a more convenient and sustainable way to make a future
therapeutic reticulocyte product for patients.36 Furthermore, when
combined with gene editing approaches using CRISPR-Cas9, these
cell lines can be enhanced further to produce an engineered thera-
peutic product designed to be compatible to a broader range of
patients.36ar Therapy: Methods & Clinical Development Vol. 17 June 2020 827
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Antibodies
Monoclonal TP antibody (clone P-GF.44C) was used at 1:10 dilution
(Thermo Scientific, Gillingham, UK). Formembrane protein analysis,
1:1 (v/v) diluted GPC (BRIC4), CD47 (BRIC32), Rh (BRIC69), Band3
(BRIC71), GPA (BRIC256), and RhAG (LA1818) (IBGRL Reagents,
Bristol, UK) were used. Secondary antibodies used were allophyco-
cyanin (APC)-conjugated monoclonal anti-mouse immunoglobulin
G (IgG)1 or polyclonal anti-IgG (BioLegend, London, UK) or Alexa
Fluor 647-anti-human (Jackson ImmunoResearch Laboratories,
Cambridgeshire, UK) and used at 1:50 (v/v). For confocal imaging,
a polyclonal GPC C-terminal antibody at 1:50 was used (in-house).
Secondary antibodies used were goat anti-rabbit-Alexa Fluor 594 (In-
vitrogen, Massachusets, USA) and goat anti-mouse-Alexa Fluor 488
(Invitrogen).BEL-A Cell Culture
BEL-A cells were cultured as previously described.17 In brief, cells
were maintained in expansion medium (StemSpan serum-free
expansion medium [SFEM; STEMCELL Technologies, Cambridge,
UK] supplemented with 50 ng/mL stem cell factor [SCF; Miltenyi
Biotec, Bisley, UK], 3 U/mL erythropoietin [EPO; Roche, Welwyn
Garden City, UK], 1 mM dexamethasone [Sigma-Aldrich, Poole,
UK], and 1 mg/mL doxycycline [Sigma-Aldrich]) at 1–3  105
cells/mL. Complete medium changes were performed every 48 h.
Differentiation was induced as previously described: cells were
seeded at 1.5  105/mL in differentiation medium (Iscove’s modi-
fied Dulbecco’s medium [IMDM], Source BioScience, Nottingham,
UK) containing 3% (v/v) AB serum (Sigma-Aldrich), 2 mg/mL hu-
man serum albumin (HSA) (Irvine Scientific, Newtown Mount
Kennedy, Ireland), 10 mg/mL insulin (Sigma-Aldrich), 3 U/mL
heparin (Sigma-Aldrich), 500 mg/mL transferrin (Sanquin Blood
Supply, the Netherlands), and 3 U/mL EPO (Roche, Welwyn Gar-
den City, UK) supplemented with 1 ng/mL interleukin (IL)-3
(R&D Systems, Abingdon, UK), 10 ng/mL SCF, and 1 mg/mL doxy-
cycline. After 2 days, cells were reseeded at 3  105/mL in fresh
medium. On differentiation day 4, cells were reseeded at 5 
105/mL in fresh medium without doxycycline. On differentiation
day 6, a complete media change was performed, and cells were re-
seeded at 1  106/mL. On day 8, cells were transferred to differen-
tiation medium (containing no SCF, IL-3, or doxycycline) and
maintained at 1  106/mL with complete medium changes every
2 days until day 12.17,36CD34+ Cell Culture
The donated blood from apheresis waste was provided with written
informed consent for research use given in accordance with the
Declaration of Helsinki from National Health Service Blood and
Transplant, Filton, Bristol, United Kingdom). The studies on erythro-
poiesis and research protocols were reviewed and approved by the
Bristol Research Ethics committee (REC Number 12/SW/0199). As
previously described,19 CD34+ hematopoietic stem cells were isolated
from human blood donor mononuclear cells or from thawed cryopre-828 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2served cord blood units by magnetic bead separation according to the
manufacturer’s instructions (Miltenyi Biotec). CD34+ cells were
grown at a density of 2 105 cells/mL using a basemedium consisting
of IMDM (Source BioScience) containing 3% (v/v) AB serum, 2 mg/
mL HSA, 10 mg/mL insulin, 3 U/mL heparin, 500 mg/mL transferrin,
and 3 U/mL erythropoietin. In the first stage (days 0–10) this was sup-
plemented with 10 ng/mL SCF and 1 ng/mL IL-3, and in the second
stage (days 11–13) with 10 ng/mL SCF. In the final stage to day 19,
only the base medium was used. 10 mM leupeptin (Sigma-Aldrich)
or 5 mM MG132 (Sigma-Aldrich) or vehicle was added at day 14 to
1  106 differentiating erythroblasts for 24 h at 37C, 5% CO2.Lentiviral Transduction
A human TP cDNA sequence was ordered and cloned in the XLG3
vector by GenScript (Leiden, the Netherlands). The original TP
sequence was mutated at sites 115 and 221 from a lysine to arginine,
thereby creating the TP-mut lentivirus as prepared according to pre-
viously published protocols.37 For transduction of BEL-A and CD34+
hematopoietic cells, virus was added to 2  105 cells in 2 mL of me-
dium in the presence of 8 mg/mL Polybrene for 24 h. Cells were
washed three times and resuspended in fresh medium.Flow Cytometry and FACS
For flow cytometry on undifferentiated BEL-A cells, 1  105 cells
were fixed in 1% paraformaldehyde and 0.0075% glutaraldehyde,
permeabilized with 0.1% Triton X-100, resuspended in PBSAG
(PBS + 1 mg/mL bovine serum albumin [BSA], 2 mg/mL glucose) +
1% BSA, and labeled with primary antibody for 30 min at 4C. Cells
were washed in PBSAG, incubated for 30 min at 4Cwith appropriate
APC-conjugated secondary antibody, and washed, and data were ac-
quired on a MACSQuant VYB analyzer using a plate reader. Reticu-
locytes were identified by gating on a Hoechst-negative population.
For FACS sorting of cells, a BD Influx cell sorter was used to isolate
single clones by sorting the propidium iodide-negative population
into 96-well plates.TP Activity Assay
1  106 cells were resuspended in lysis buffer (50 mM Tris-HCl [pH
7.2], 1% [w/v] Triton X-100, 2 mM phenylmethylsulfonyl fluoride
[PMSF], 0.02% [v/v] 2-mercaptoethanol). The lysate was centrifuged
at 16,000  g for 30 min at 4C and then 176 mM thymidine and 5
TP reaction buffer (0.5 M Tris-arsenate [pH 6.5]) was added to the
supernatant. The controls used were lysis buffer alone or lysis buffer
containing known concentrations of purified TP protein (Sigma-Al-
drich). The reaction was incubated at 37C for 60min and then termi-
nated by addition of 0.3 M NaOH. The absorbance was measured us-
ing a spectrophotometer at 299 nm and compared to the TP enzyme
standard concentration curve.38Cytospin Staining
1  105 cells were cytospun onto glass slides, fixed in methanol, and
stained with May-Grünwald-Giemsa stains according to the manu-
facturer’s protocol. Images were taken with a Leica DM750020
www.moleculartherapy.orgmicroscope coupled to an Olympus U-TVO.5XC-3 camera using a
40 lens and processed using Adobe Photoshop 9.0 (Adobe Systems).Immunofluorescence
5  105 cells were fixed in suspension in 1% paraformaldehyde and
0.0075% glutaraldehyde and washed three times in PBSAG before be-
ing cytospun onto coated coverslips. Cells were then permeabilized
with 0.05% Triton X-100 for 5 min at room temperature and
then blocked in PBS-4% BSA for 45 min, incubated with primary
antibodies in PBS-4% BSA for 1 h, washed with PBS, and incubated
for 1 h with the appropriate secondary antibodies. Coverslips
were washed and mounted on microscope slides using Mowiol
(Calbiochem, San Diego, USA) containing 2.5% (w/v) DABCO anti-
fade reagent (Sigma-Aldrich). Confocal images were taken using a Le-
ica SPE single-channel confocal laser scanning microscope attached
to a Leica DMi8 inverted epifluorescence microscope.SDS-PAGE and Western Blotting
1  106 cells were taken at designated time points during differenti-
ation and pelleted, snap-frozen, and stored at 80C. Pellets were
lysed for 10 min on ice in lysis buffer (20 mM Tris-HCl [pH 8.0],
137 mM NaCl, 10 mM EDTA, 100 mM NaF, 1% [v/v] Nonidet P-
40, 10% [v/v] glycerol, 10 mM Na3VO4, 2 mM PMSF, and protease
inhibitors [Calbiochem]). Equal numbers of lysed cells were loaded
and separated by SDS-PAGE and then immunoblotted.Reticulocyte Deformability Measurements Using ARCA
1  106 reticulocytes were resuspended in 200 mL of polyvinylpyrro-
lidone (PVP) solution (viscosity, 28.1; Mechatronics Instruments, the
Netherlands). Samples were assayed in an ARCA (automated rheo-
scope and cell analyser) assay,39 which consists of a plate-to-plate op-
tical shearing stage (model CSS450) mounted on a Linkam imaging
station assembly and temperature controlled using Linksys32 soft-
ware (Linkam Scientific Instruments, Surrey, UK) at 37C with 3
Pa. The microscope was equipped with an LMPlanFl 50 objective
lens with a 10.6-mm working distance objective (Olympus, Essex,
UK) illuminated by an X-1500 stroboscope (PerkinElmer, the
Netherlands) through a band-pass interference filter (center wave-
length [CWL], 420 nm; full width at half maximum [FWHM],
10 nm; Edmund Optics, Poppleton, UK). Images were acquired using
a uEye camera (UI-2140SE-M-GL; IDS, Obersulm, Germany). At
least 1,000 cell images per sample were acquired and analyzed using
bespoke ARCA software. In this analysis the distribution of the sur-
face area of the red blood cells within the sample as observed in the
ARCA assay was estimated as well as the distribution of the degree
of deformation of the red blood cells due to the imposed shear stress.TP Modeling
Ubiquitination sites were predicted from mUbiSiDa, a database of
mammalian protein ubiquitination sites (https://omictools.com/
mubisida-tool), which provided details of the mouse ubiquitination
sites analyzed in Wagner et al.27 Clustal Omega (http://www.clustal.
org/omega/) was used to align human and mouse sequences. ProteinMoleculstructures were visualized, and images were produced with UCSF
Chimera software (https://www.cgl.ucsf.edu/chimera/).
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